The antiviral remdesivir treatment reduced the risk of hospitalization among COVID-19 patients when administered soon after they were diagnosed, according to a new study from Gilead Sciences, which developed remdesivir.
Researchers found that remdesivir cut the risk of hospitalization by 87 percent compared to a placebo that half of the study participants received.
